BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 34823428)

  • 21. When a Monoclonal Gammopathy Is Not Multiple Myeloma.
    Derman B; Castillo JJ; Sarosiek S; Beksac M
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-10. PubMed ID: 35394823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA
    Eur J Haematol Suppl; 1989; 51():70-5. PubMed ID: 2516809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
    Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
    Kyle RA; Durie BG; Rajkumar SV; Landgren O; Blade J; Merlini G; Kröger N; Einsele H; Vesole DH; Dimopoulos M; San Miguel J; Avet-Loiseau H; Hajek R; Chen WM; Anderson KC; Ludwig H; Sonneveld P; Pavlovsky S; Palumbo A; Richardson PG; Barlogie B; Greipp P; Vescio R; Turesson I; Westin J; Boccadoro M;
    Leukemia; 2010 Jun; 24(6):1121-7. PubMed ID: 20410922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of the target of monoclonal immunoglobulins: a novel diagnostic tool for individualized MGUS therapy, and prevention and therapy of smoldering and multiple myeloma.
    Hermouet S; Bigot-Corbel E; Harb J
    Front Immunol; 2023; 14():1253363. PubMed ID: 38022528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal Gammopathy of Undetermined Significance.
    Gonsalves WI; Rajkumar SV
    Ann Intern Med; 2022 Dec; 175(12):ITC177-ITC192. PubMed ID: 36508741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paraproteinemic Keratopathy: The Expanding Diversity of Clinical and Pathologic Manifestations.
    Milman T; Kao AA; Chu D; Gorski M; Steiner A; Simon CZ; Shih C; Aldave AJ; Eagle RC; Jakobiec FA; Udell I
    Ophthalmology; 2015 Sep; 122(9):1748-56. PubMed ID: 26118999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review.
    Kaur J; Valisekka SS; Hameed M; Bandi PS; Varma S; Onwughalu CJ; Ibrahim H; Mongia H
    Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):e195-e212. PubMed ID: 36966041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does my patient with a serum monoclonal spike have multiple myeloma?
    Bianchi G; Ghobrial IM
    Hematol Oncol Clin North Am; 2012 Apr; 26(2):383-93, ix. PubMed ID: 22463833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Smoldering multiple myeloma 40 years later: a story of unintended disease.
    Yavorkovsky LL
    Expert Rev Hematol; 2021 Feb; 14(2):149-153. PubMed ID: 33430658
    [No Abstract]   [Full Text] [Related]  

  • 33. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management.
    Maciocia N; Wechalekar A; Yong K
    Hematol Oncol; 2017 Dec; 35(4):432-439. PubMed ID: 27804161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does Systemic Hematological Therapy Influence the Course of Paraproteinemic Keratopathy?
    Al Hariri M; Munder M; Pfeiffer N; Wasielica-Poslednik J
    J Clin Med; 2024 Jan; 13(2):. PubMed ID: 38256698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
    Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Cairns DA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
    Lancet Haematol; 2017 Dec; 4(12):e584-e594. PubMed ID: 29146225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma.
    Wadhera RK; Kyle RA; Larson DR; Dispenzieri A; Kumar S; Lazarus HM; Rajkumar SV
    Blood; 2011 Sep; 118(11):2985-7. PubMed ID: 21765020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Corneal deposits in monoclonal gammopathy of undetermined significance. Review of the literature and case report].
    Németh O; Tapasztó B; Tar S; Szabó V; Nagy ZZ; Tóth J; Hamed A; Mikala G; Szentmáry N
    Orv Hetil; 2018 Sep; 159(39):1575-1583. PubMed ID: 30543127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.
    Korde N; Kristinsson SY; Landgren O
    Blood; 2011 May; 117(21):5573-81. PubMed ID: 21441462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches.
    Lagreca I; Riva G; Nasillo V; Barozzi P; Castelli I; Basso S; Bettelli F; Giusti D; Cuoghi A; Bresciani P; Messerotti A; Gilioli A; Pioli V; Colasante C; Vallerini D; Paolini A; Maccaferri M; Donatelli F; Forghieri F; Morselli M; Colaci E; Leonardi G; Marasca R; Potenza L; Manfredini R; Tagliafico E; Trenti T; Comoli P; Luppi M
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
    Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
    Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.